查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087421

可吸收血管支架市場：依材料、適應症、藥物釋放型類型、支架長度及最終用戶分類－2026-2032年全球市場預測

Resorbable Vascular Scaffold Market by Material Type, Indication Type, Drug Elution Type, Scaffold Length, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，可吸收血管支架市場將成長至 7.7998 億美元，複合年成長率為 7.68%。

主要市場統計數據
基準年 2025 4.6465億美元
預計年份：2026年 5.068億美元
預測年份 2032 7.7998億美元
複合年成長率 (%) 7.68%

可吸收血管支架（RVS）是新一代冠狀動脈介入治療平台，旨在透過在逐漸被吸收前提供臨時血管支撐和藥物輸送，幫助恢復血管動力、減少永久性金屬支架的使用，並保留未來的治療選擇。可吸收血管支架市場的發展仍受到第一代生物可吸收血管支架（BVS）計畫經驗的影響。這其中包括獲得FDA批准的Absorb GT1 BVS，該產品後來由於臨床應用和推廣方面的挑戰（包括在對比臨床隨訪研究中發現的問題）而撤出市場。

目前的商業機會主要集中在改進支架結構、減少支架梁厚度、開發鎂和聚合物平台、最佳化植入方案以及提高患者和病變選擇的準確性。對於製造商而言，競爭優勢不再僅基於新穎性，而是取決於證明其產品在臨床上不劣於或優於現有的藥物釋放型支架、具有長期安全性、可預測的吸收率以及在實際導管檢查室手術中的效率。

重塑RVS創新格局的變革性變化

可吸收血管支架領域正從最初的熱情轉向基於實證醫學的產品開發。早期的聚合物支架已證實支架梁厚度、徑向強度、擴張極限和留置技術在臨床上的重要性。因此，下一代產品的開發重點在於更薄的支架壁、更佳的植入性、更短且更可預測的吸收期以及更穩定的血管癒合。

人工智慧（AI）對RVS的累積影響

人工智慧 (AI) 透過增強設計、臨床試驗執行和臨床決策支持，累積提升血管支架 (RVS) 的價值鏈。在研發 (R&D) 階段，AI 驅動的模擬能夠在昂貴的原型製作之前評估支架形狀、徑向強度、分解行為以及與血管的相互作用。此外，將機器學習應用於血管內成像可以更精確地測量血管尺寸、評估鈣化程度、表徵斑塊特徵並篩選病灶。

關於RVS實施的關鍵區域見解

亞太地區（包括中國、日本、印度、韓國和澳洲）由於心血管疾病負擔沉重且介入性心臟病學能力不斷提升，正成為增強型陰道支架（RVS）研發和應用的關鍵區域。日本和韓國則注重嚴謹的臨床證據、精密製造和品管體系，而中國和印度則以手術量巨大、醫院基礎設施完善以及國內醫療技術創新不斷成長為特徵。澳洲優先考慮註冊登記，並提供循證應用環境，支持對新型冠狀動脈支架技術進行謹慎評估。

戰略市場板塊的關鍵群體洞察

東協市場對RVS未來的擴張具有吸引力，因為新加坡、泰國、馬來西亞、印尼、越南和菲律賓的都市區心臟中心正在加強其導管室的能力。然而，由於報銷方案和培訓項目的差異，商業化和醫生培訓需要分階段進行。海灣合作理事會（GCC）國家的特點是心血管疾病風險因素高、擁有先進的三級醫療機構，並且對高階心血管技術有著強勁的需求，尤其是在政府資助的醫療保健和專家轉診計劃支持採用先進心臟介入設備的地區。

來自吸收性支架市場主要國家的洞察

就監管信譽而言，美國是最具影響力的RVS市場，但其廣泛應用需要有明確的證據表明，與主流藥物釋放型支架相比，RVS具有長期安全性和治療效果，並需有嚴格的臨床隨訪研究和真實世界臨床數據支持。在加拿大，基於實證醫學的採購和報銷審查機制已經建立；而如果能夠消除定價、影像檢查和操作者培訓方面的障礙，墨西哥和巴西則具有區域需求成長的潛力。英國、德國、法國、義大利和西班牙仍然是歐洲重要的臨床中心，其中德國在介入性心臟病學創新、醫院評估和早期專家參與方面發揮關鍵作用。

為房車行業領導者提供的實用建議

產業領導者應優先考慮具有臨床意義的差異化，而非籠統地宣稱生物吸收率。研發項目應包含預先設定的影像學終點、樣本量充足的隨機對照試驗以及長期追蹤研究，重點關注支架血栓症、目標病變失敗、延遲性管腔狹窄、血管癒合和血管舒縮功能恢復。相關證據應與目前一代藥物釋放型支架進行比較，而非與老一代支架進行比較。

RVS市場分析的調查方法

本執行摘要基於系統的二手研究方法，利用公開的監管記錄、同行評審的臨床文獻、臨床研究途徑，包括第一代支架的臨床結果、法規核准流程、產品退市、不斷發展的醫療設備評估標準以及冠狀動脈影像引導介入治療的進展。

結論：證據將決定RVS的未來。

可吸收血管支架市場已進入更成熟的階段，其特徵是科學嚴謹性、選擇性應用和新一代技術發展。該領域的長期潛力依然極具吸引力，因為臨時血管支撐滿足了「治療冠狀動脈疾病而不留下永久性植入」這一尚未滿足的臨床需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 可吸收血管支架市場：依材料類型分類

  • 聚合物基
    • 聚左旋乳酸（PLLA）
    • 聚乙醇酸（PGA）
    • 聚己內酯（PCL）
    • 氧環己酮聚合體（PDO）
  • 金屬
    • 鎂合金
    • 鐵基合金
    • 鋅合金

第8章 可吸收血管支架市場：依適應症類型分類

  • 缺血性心臟疾病
  • 周邊動脈疾病
    • 股動脈疾病
    • 膕動脈疾病
    • 脛動脈疾病

第9章 可吸收血管支架市場：依藥物釋放型類型分類

  • 藥物釋放型支架
    • Sirolimus洗脫型
    • Everolimus洗脫型
    • 紫杉醇洗脫型
    • Biolims溶解型
  • 非藥物釋放型支架

第10章 可吸收血管支架市場：依支架長度分類

  • 18-28毫米
  • 超過28毫米
  • 小於18毫米

第11章 可吸收血管支架市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第12章 可吸收血管支架市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 可吸收血管支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 可吸收血管支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Balton Sp. z oo
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co., Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Lifetech Scientific Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • REVA Medical LLC
  • Sahajanand Medical Technologies Pvt. Ltd.
  • Terumo Corporation
  • Translumina Therapeutics LLP
  • Zorion Medical Inc.
Product Code: MRR-035AB9C0DAAB

The Resorbable Vascular Scaffold Market is projected to grow by USD 779.98 million at a CAGR of 7.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 464.65 million
Estimated Year [2026] USD 500.68 million
Forecast Year [2032] USD 779.98 million
CAGR (%) 7.68%

Resorbable vascular scaffolds (RVS) represent a next-generation coronary intervention platform designed to provide temporary vessel support and drug delivery, then gradually resorb to help restore vasomotion, reduce permanent metallic caging, and preserve future treatment options. The resorbable vascular scaffold market remains shaped by lessons from first-generation bioresorbable vascular scaffold programs, including the FDA-approved Absorb GT1 BVS, which was later withdrawn from commercial sale after clinical and adoption challenges, including concerns identified in comparative clinical follow-up.

Current opportunity is concentrated in improved scaffold architecture, thinner struts, magnesium and polymer platforms, optimized implantation protocols, and better patient and lesion selection. For manufacturers, the competitive path is no longer based on novelty alone; it depends on demonstrating clinical noninferiority or superiority versus contemporary drug-eluting stents, durable safety, predictable resorption, and procedural efficiency in real-world catheterization labs.

Transformative Shifts Reshaping RVS Innovation

The resorbable vascular scaffold landscape is shifting from first-generation enthusiasm to evidence-led product discipline. Earlier polymeric scaffolds showed the clinical importance of strut thickness, radial strength, expansion limits, and implantation technique. As a result, next-generation development is prioritizing thinner profiles, improved deliverability, shorter and more predictable resorption timelines, and more consistent vessel healing.

Regulatory expectations have also transformed. The U.S. FDA, European regulators under the Medical Device Regulation, and major Asian agencies increasingly require robust randomized data, long-term follow-up, and post-market surveillance. This favors organizations with strong clinical operations, material science expertise, imaging-guided procedure support, and physician education models that reduce scaffold thrombosis risk through correct sizing, lesion preparation, and high-pressure post-dilatation.

Cumulative Impact of Artificial Intelligence on RVS

Artificial intelligence is cumulatively improving the RVS value chain by strengthening design, trial execution, and clinical decision support. In R&D, AI-enabled simulation can evaluate scaffold geometry, radial force, degradation behavior, and vessel interaction before costly prototyping. Machine learning applied to intravascular imaging may also support more precise vessel sizing, calcium assessment, plaque characterization, and lesion selection.

In clinical development, AI can improve site selection, patient stratification, adverse-event signal detection, and real-world evidence generation. Its most immediate commercial impact is likely to be procedural optimization: integrating angiography, OCT, IVUS, and electronic health record data to identify patients most likely to benefit from temporary scaffolding while reducing inappropriate use in complex lesions where metallic drug-eluting stents remain better validated.

Key Regional Insights for RVS Adoption

Asia-Pacific is becoming an important RVS development and adoption arena because China, Japan, India, South Korea, and Australia combine high cardiovascular disease burden with expanding interventional cardiology capacity. Japan and South Korea emphasize rigorous clinical evidence, precision manufacturing, and quality systems, while China and India offer large procedural volumes, improving hospital infrastructure, and growing domestic medtech innovation. Australia contributes a registry-oriented and evidence-based adoption environment that supports careful evaluation of new coronary scaffold technologies.

North America remains evidence-driven, with the United States and Canada requiring strong safety data after the first-generation bioresorbable vascular scaffold experience. Europe continues to influence clinical standards through high-volume research centers and interventional cardiology networks, although Medical Device Regulation requirements have raised evidence, documentation, and compliance thresholds. Latin America, led by Brazil and Mexico, presents selective opportunities where adoption will depend on pricing discipline, reimbursement clarity, and training access. The Middle East, particularly advanced tertiary systems in Gulf countries, shows potential for premium cardiovascular technologies where specialist infrastructure is available, while Africa remains a longer-term opportunity constrained by uneven cath lab access, affordability, and advanced imaging availability.

Key Group Insights Across Strategic Market Blocs

ASEAN markets are attractive for future RVS expansion because urban cardiac centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are upgrading cath lab capabilities, but reimbursement and training variability require staged commercialization and physician education. The GCC is characterized by high cardiovascular risk factors, advanced tertiary hospitals, and strong demand for premium cardiovascular technologies, particularly where government-funded care and specialist referral systems support adoption of advanced interventional cardiology devices.

The European Union remains central for clinical evidence generation, harmonized regulatory scrutiny, and post-market vigilance, but Medical Device Regulation compliance increases documentation, clinical evaluation, and surveillance obligations. BRICS countries offer procedural scale, local manufacturing potential, and diverse access models, with China and India especially relevant for domestic device development and clinical volume. G7 markets set expectations for long-term safety, reimbursement evidence, registry transparency, and physician consensus. NATO membership is not a market driver by itself, but many NATO countries overlap with advanced procurement, regulatory, and hospital systems relevant to cardiovascular devices.

Key Country Insights in Resorbable Scaffold Markets

The United States is the most influential RVS market for regulatory credibility, but adoption depends on clear long-term safety and comparative outcomes versus leading drug-eluting stents, supported by rigorous clinical follow-up and real-world evidence. Canada follows evidence-based procurement and reimbursement scrutiny, while Mexico and Brazil offer regional volume potential if pricing, imaging access, and operator training barriers are addressed. The United Kingdom, Germany, France, Italy, and Spain remain important European clinical hubs, with Germany particularly relevant for interventional cardiology innovation, hospital-based evaluation, and early specialist engagement.

Russia presents a more complex access environment shaped by sanctions, localization requirements, supply chain restrictions, and procurement constraints. China and India offer large patient populations, expanding interventional cardiology capacity, and active domestic device ecosystems, making them central to future RVS development and adoption strategies. Japan and South Korea demand high-quality evidence, precision manufacturing, and strong regulatory documentation, while Japan's aging population and South Korea's advanced hospital systems support focused evaluation of coronary innovation. Australia is a sophisticated but smaller market where reimbursement, specialist endorsement, clinical registries, and outcomes transparency strongly influence uptake.

Actionable Recommendations for RVS Industry Leaders

Industry leaders should prioritize clinically meaningful differentiation rather than broad claims of bioresorption. Development programs need predefined imaging endpoints, adequately powered randomized trials, and long-term follow-up focused on scaffold thrombosis, target lesion failure, late lumen loss, vessel healing, and restoration of vasomotion. Evidence should be benchmarked against current-generation drug-eluting stents, not against older platforms.

Commercial teams should build adoption around training-certified implantation protocols, including lesion preparation, accurate sizing, and post-dilatation. Integration with OCT and IVUS workflows can improve procedural consistency and support appropriate patient selection. Organizations should also design market access strategies early, combining health economics, registry data, and real-world evidence to demonstrate where temporary scaffolding creates value for patients, clinicians, and payers.

Research Methodology for RVS Market Analysis

This executive summary is based on a structured secondary research approach using publicly available regulatory records, peer-reviewed clinical literature, clinical trial publications, medical society discussions, product documentation, and market intelligence on interventional cardiology technologies. Emphasis is placed on verified developments such as first-generation scaffold clinical outcomes, regulatory approval pathways, commercial withdrawals, evolving device evaluation standards, and advances in coronary imaging-guided intervention.

The methodology prioritizes triangulation across clinical trials, registries, product documentation, regulatory communications, and regional healthcare infrastructure indicators. Insights are interpreted through the lens of device safety, procedural adoption, reimbursement feasibility, clinical workflow integration, and competitive positioning versus contemporary drug-eluting stents. No unverified market-size figures are used; conclusions focus on evidence-backed directional trends and strategic implications.

Conclusion: Evidence Will Define the RVS Future

The resorbable vascular scaffold market is entering a more mature phase defined by scientific rigor, selective adoption, and next-generation engineering. The category's long-term potential remains compelling because temporary vascular support addresses an unmet clinical aspiration: treating coronary lesions without leaving a permanent implant behind.

However, the path to sustainable growth requires proof. Manufacturers must demonstrate safer scaffold design, predictable degradation, procedural reproducibility, and patient-specific value. Markets with strong clinical governance, intravascular imaging capability, trained operators, and reimbursement sophistication will likely lead early adoption, while broader global expansion will depend on cost-effectiveness, supply reliability, and training. The winners will be organizations that translate bioresorption from an appealing concept into consistently validated cardiovascular outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Resorbable Vascular Scaffold Market, by Material Type

  • 7.1. Polymer-based
    • 7.1.1. Poly-L-lactic Acid (PLLA)
    • 7.1.2. Poly-glycolic Acid (PGA)
    • 7.1.3. Polycaprolactone (PCL)
    • 7.1.4. Poly-dioxanone (PDO)
  • 7.2. Metal-based
    • 7.2.1. Magnesium Alloys
    • 7.2.2. Iron-based Alloys
    • 7.2.3. Zinc-based Alloys

8. Resorbable Vascular Scaffold Market, by Indication Type

  • 8.1. Coronary Artery Disease
  • 8.2. Peripheral Arterial Disease
    • 8.2.1. Femoral Artery Disease
    • 8.2.2. Popliteal Artery Disease
    • 8.2.3. Tibial Artery Disease

9. Resorbable Vascular Scaffold Market, by Drug Elution Type

  • 9.1. Drug Eluting Scaffolds
    • 9.1.1. Sirolimus Eluting
    • 9.1.2. Everolimus Eluting
    • 9.1.3. Paclitaxel Eluting
    • 9.1.4. Biolimus Eluting
  • 9.2. Non Drug Eluting Scaffolds

10. Resorbable Vascular Scaffold Market, by Scaffold Length

  • 10.1. 18 To 28 Millimeter
  • 10.2. Greater Than 28 Millimeter
  • 10.3. Less Than 18 Millimeter

11. Resorbable Vascular Scaffold Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Resorbable Vascular Scaffold Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Resorbable Vascular Scaffold Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Resorbable Vascular Scaffold Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Balton Sp. z o.o.
  • 16.3. Biotronik SE & Co. KG
  • 16.4. Boston Scientific Corporation
  • 16.5. Cook Medical LLC
  • 16.6. Elixir Medical Corporation
  • 16.7. Kyoto Medical Planning Co., Ltd.
  • 16.8. Lepu Medical Technology (Beijing) Co., Ltd.
  • 16.9. Lifetech Scientific Corporation
  • 16.10. Meril Life Sciences Pvt. Ltd.
  • 16.11. MicroPort Scientific Corporation
  • 16.12. OrbusNeich Medical Company Limited
  • 16.13. REVA Medical LLC
  • 16.14. Sahajanand Medical Technologies Pvt. Ltd.
  • 16.15. Terumo Corporation
  • 16.16. Translumina Therapeutics LLP
  • 16.17. Zorion Medical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POLYMER-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POLYMER-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POLYMER-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METAL-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METAL-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METAL-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 160. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 161. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 166. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 190. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 191. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 196. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 200. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 201. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 206. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY P